Cobalt has advised venture capital fund Practica Capital on its investment in Lithuanian biotech startup Droplet Genomics. Triniti reportedly advised Droplet Genomics on the investment round, which included other business angel investors and amounted to EUR 1 million.
Droplet Genomics aims to commercialize droplet micro-fluidics technology, which enables researchers to study single cells and single molecules. According to Cobalt, “experiments performed at such resolution, allow scientists to uncover new facets of human biology, diseases and speed up drug discovery research. Droplet Genomics develops hardware systems, consumables, and software solutions. They intend to create easy to use workflows that would enable researchers to tap into the potential of droplet micro-fluidics technology for studying complex biological systems, as well as high-throughput screening applications.” According to the firm, “this investment will enable Droplet Genomics to expand its intellectual property portfolio and accelerate the commercialization of new products.”
Cobalt’s team included Partner Eva Suduiko and Senior Associate Aurelija Balciune.
